Initial therapeutic strategy of invasive candidiasis for intensive care unit patients: a retrospective analysis from the China-SCAN study

Table 1 Baseline characteristics of 268 ICI patients receiving antifungal therapy in the China-SCAN study

Variables	Empirical N = 142	Pre-emptive N = 53	Targeted N = 73	P-value
Age, years	58.3 ± 21.6	58.3 ± 18.4	68.7 ± 16.2	0.001
Gender, n (%)				0.414
Male	98 (69.0)	40 (75.5)	47 (64.4)
Female	44 (31.0)	13 (24.5)	26 (35.6)
Body weight, kg	61.8 ± 10.7	63.5 ± 10.4	63.8 ± 10.1	0.473
Hospital stays before ICU admission, days	0.5 (10.0)	1.0 (4.5)	0.0 (11.5)	0.829
ICU stays before candidiasis onset, days	9.0 (17.0)	10.0 (14.5)	11.0 (33.0)	0.717
Hospital stays before candidiasis onset, days	16.5 (23.3)	12.0 (24.5)	16.0 (41.0)	0.461
Underlying disease, n (%)
Diabetic mellitus	28 (19.7)	13 (24.5)	21 (28.8)	0.318
Chronic cardiac dysfunction^a	23 (16.2)	14 (26.4)	17 (23.3)	0.210
Chronic obstructive pulmonary disease	15 (10.6)	6 (11.3)	12 (16.4)	0.449
Chronic renal insufficiency^b	12 (8.5)	5 (9.4)	13 (17.8)	0.108
Chronic hepatic insufficiency^c	4 (2.8)	1 (1.9)	6 (8.2)	0.111
Solid tumor	26 (18.3)	7 (13.2)	17 (23.3)	0.353
Haematological malignancy	2 (1.4)	1 (1.9)	-	0.545
Illness severity at ICU admission
APACHE II score	20.0 ± 9.2	20.9 ± 8.1	21.5 ± 8.6	0.517
SOFA score	7.2 ± 3.7	7.7 ± 3.4	6.8 ± 3.8	0.434

Continuous variables are expressed as the means ± SD or medians (IQR). All the other data are raw numbers (%)
APACHE II Acute Physiology and Chronic Health Evaluation II, SOFA sequential organ failure assessment
^aAll patients corresponding to the New York Heart Association (NYHA) standards of level II or higher
^bAll patients receiving long-term hemodialysis
^cAs described according to APACHE II criteria: biopsy-proven cirrhosis and documented portal hypertension; episodes of past upper gastrointestinal bleeding attributed to portal hypertension; or prior episodes of hepatic failure/encephalopathy/coma

ISSN: 1471-2334